ValuEngine upgraded shares of PLx Pharma (NASDAQ:PLXP) from a strong sell rating to a sell rating in a report published on Monday.
Separately, Zacks Investment Research lowered shares of PLx Pharma from a buy rating to a sell rating in a report on Tuesday, October 3rd.
Shares of PLx Pharma (NASDAQ PLXP) traded up $0.25 on Monday, hitting $6.90. 36,900 shares of the company’s stock were exchanged, compared to its average volume of 14,077. PLx Pharma has a 52 week low of $5.60 and a 52 week high of $22.00. The company has a current ratio of 8.99, a quick ratio of 8.88 and a debt-to-equity ratio of 0.56.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in PLx Pharma during the 3rd quarter valued at about $145,000. University of Texas Investment Managment Co. bought a new stake in shares of PLx Pharma in the 2nd quarter worth approximately $385,000. Finally, Susquehanna International Group LLP bought a new stake in shares of PLx Pharma in the 2nd quarter worth approximately $1,413,000. 21.87% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “PLx Pharma (PLXP) Raised to “Sell” at ValuEngine” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2017/12/07/plx-pharma-plxp-raised-to-sell-at-valuengine.html.
PLx Pharma Company Profile
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for PLx Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.